go-v.orgdoi

Sofosbuvir for the treatment of patients with genotype 2 or 3 chronic hepatitis C virus infection

Christoph Höner zu Siederdissen, Markus Cornberg · Clinical Investigation · 2014

  • DOI 10.4155/cli.14.24
  • Publisher OMICS Publishing Group
  • Type article
  • Issued 2014

Not cached yet. This record was fetched live for this request and is stored after the lookup. Reopening the page should serve the cached copy.

Clinical Investigation · OMICS Publishing Group · article · 2014

Abstract

Treatment of chronic hepatitis C will dramatically change with the introduction of direct antiviral agents that allow interferon-free treatment schedules. However, most of the currently developed direct antiviral agents focus on genotype 1. Thus, other genotypes, especially genotype 3 will become more difficult to treat with interferon-free regimens in the near future in comparison with genotype 1. Hepatitis C virus genotype 3 may convert to the most problematic genotype as not only interferon-free therapies are more challenging but also progression to cirrhosis is faster.

Sofosbuvir, a NS5B nucleoside HCV polymerase inhibitor is one of the direct antiviral agents that has pangenotypic efficacy. Phase III trials investigating sofosbuvir plus ribavirin treatment in patients with hepatitis C virus genotype 2 and 3 infection have been completed and sofosbuvir was approved by the US FDA and European Medicines Agency.

Open the resolved locator · 10.4155/cli.14.24

Metadata licence: OpenAlex metadata (CC0)

Registry
OpenAlex DOI index + API
Fetched
2026-11-20 10:29 UTC
Cache state
not cached yet (bulk-index+openalex)
Locator
https://doi.org/10.4155/cli.14.24
Metadata licence
OpenAlex metadata (CC0)
Scope
Metadata as returned by the resolver; abstracts are never generated here.